|Day's range||117.26 - 117.26|
|52-week range||101.71 - 120.18|
|PE ratio (TTM)||N/A|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
Celgene is expected to report healthy 2Q earnings thanks to its blockbuster cancer drug Revlimid.
For generic drug companies, manufacturing low-cost alternatives to brand-name medicines is the easy part. The hard part: getting their hands on the drugs they want to copy.
The July 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.